Claims for Patent: 8,372,860

Summary for Patent: 8,372,860

Title:	Carboline derivatives useful in the inhibition of angiogenesis
Abstract:	In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.
Inventor(s):	Moon; Young-Choon (Belle Mead, NJ), Cao; Liangxian (Parlin, NJ), Tamilarasu; Nadarajan (Edison, NJ), Qi; Hongyan (Plainsboro, NJ), Choi; Soongyu (Skillman, NJ), Lennox; William Joseph (South Plainfield, NJ), Corson; Donald Thomas (Annandale, NJ), Hwang; Seongwoo (Edison, NJ), Davis; Thomas (South Orange, NJ)
Assignee:	PTC Therapeutics, Inc. (South Plainfield, NJ)
Application Number:	12/715,651
Patent Claims:	1. A method for treating a solid tumor cancer comprising administering a therapeutically effective amount of a compound of formula: ##STR00379## or a pharmaceutically acceptable salt, racemate or stereoisomer of said compound, to a subject in need thereof; wherein: X is halogen; R.sub.o is halogen, substituted or unsubstituted C.sub.1 to C.sub.8 alkyl or OR.sub.a; R.sub.a is H or C.sub.1 to C.sub.8 alkyl optionally substituted with one or more substituents independently selected from hydroxyl and halogen; and R.sub.d is phenyl substituted with one or more alkoxy or halogen substituents, wherein the compound inhibits VEGF production in a HT1080 solid tumor grown in a nude mouse, inhibits HT1080 solid tumor growth in a nude mouse or inhibits angiogenesis in a HT1080 solid tumor grown in a nude mouse. 2. The method of claim 1, wherein the compound has the formula: ##STR00380## or a pharmaceutically acceptable salt, racemate or stereoisomer thereof, wherein, X is halogen; R.sub.o is OR.sub.a; R.sub.a is H or C.sub.1 to C.sub.8 alkyl optionally substituted with one or more substituents independently selected from hydroxyl and halogen; and R.sub.d is phenyl substituted with one or more alkoxy or halogen substituents. 3. The method of claim 1, wherein the compound has the formula: ##STR00381## or a pharmaceutically acceptable salt, racemate or stereoisomer thereof, wherein, X is halogen; R.sub.a is H or C.sub.1 to C.sub.8 alkyl optionally substituted with one or more substituents independently selected from hydroxyl and halogen; and R.sub.d is phenyl substituted with one or more halogen substituents. 4. The method of claim 1, wherein the compound has the formula: ##STR00382## or a pharmaceutically acceptable salt, racemate or stereoisomer thereof, wherein, X is halogen; R.sub.a is C.sub.1 to C.sub.8 alkyl optionally substituted with one or more substituents independently selected from hydroxyl and halogen; and R.sub.d is phenyl substituted at the para position with a halogen substituent. 5. The method of claim 4, wherein X is chloro. 6. The method of claim 5, wherein R.sub.d is phenyl substituted at the para position with chloro. 7. The method of claim 6, wherein R.sub.a is unsubstituted C.sub.1 to C.sub.8 alkyl. 8. The method of claim 6, wherein R.sub.a is C.sub.1 to C.sub.8 alkyl substituted with one or more hydroxyl substituents. 9. The method of claim 1 or 2, wherein said compound has a chiral carbon at the point of attachment of the R.sub.a substituted phenyl and said compound is an (S) isomer at said chiral carbon. 10. The method of any of claims 3-8, wherein said compound has a chiral carbon at the point of attachment of the OR.sub.a substituted phenyl and said compound is an (S) isomer at said chiral carbon. 11. The method of claim 1, wherein the compound has an EC.sub.50 of less than 50 nM for inhibiting hypoxia-induced VEGF expression in cultured HeLa cells. 12. The method of claim 1, wherein the compound inhibits VEGF production in a HT1080 solid tumor grown in a nude mouse. 13. The method of claim 1, wherein the compound inhibits HT1080 solid tumor growth in a nude mouse. 14. The method of claim 1, wherein the compound inhibits angiogenesis in a HT1080 solid tumor grown in a nude mouse. 15. A method for treating a solid tumor cancer comprising administering a therapeutically effective amount of a compound to a subject having a solid tumor cancer, wherein said compound is ##STR00383## or a pharmaceutically acceptable salt thereof, wherein the compound inhibits VEGF production in a HT 1080 solid tumor grown in a nude mouse, inhibits HT1080 solid tumor growth in a nude mouse or inhibits angiogenesis in a HT 1080 solid tumor grown in a nude mouse. 16. The method as in claim 1 or 15, wherein said compound is administered simultaneously or sequentially with one or more additional agents useful in the treatment of cancer. 17. The method of claim 16, wherein said one or more additional agents useful in the treatment of cancer is selected from the group consisting of paclitaxel, fluorouracil, irinotecan, thalidomide, gemcitabine, squalamine, endostatin, angiostatin, neovastat, lenalidomide, vitaxin, 2-methoxyestradiol, carboxyamidotriazole, combretastatin A4 phosphate, 5-[1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3- -propanoic acid, sunitinib malate, rebimastat, metastat, cilengitide, ramucirumab, vatalanib, enzastaurin, aflibercept, vandetanib, halofuginone hydrobromide, celecoxib, interferon alpha, interleukin-12, and bevacizumab. 18. The method of claim 17, wherein said one or more additional agents are selected from bevacizumab, paclitaxel and fluorouracil. 19. The method as in claim 1 or 15, wherein the solid tumor cancer is selected from the group consisting of a solid tumor carcinoma and a solid tumor sarcoma. 20. The method as in claim 1 or 15, wherein the solid tumor cancer is selected from the group consisting of a pediatric solid tumor, a carcinoma of the epidermis, a cervical carcinoma, a cervical cancer, a colon carcinoma, a colon cancer, a lung carcinoma, a lung cancer, a renal carcinoma and a renal cancer. 21. The method as in claim 1 or 15, wherein the solid tumor cancer is selected from a group consisting of a Wilms tumor, a neuroblastoma and a malignant melanoma.

Details for Patent 8,372,860

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2025-03-15
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	11/18/2011		2025-03-15
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	08/16/2018		2025-03-15
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	04/21/2014		2025-03-15